We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+1.62%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$825M
AUM Growth
-$13.1M
Cap. Flow
-$4.93M
Cap. Flow %
-0.6%
Top 10 Hldgs %
40.43%
Holding
69
New
13
Increased
13
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$35.8M
2
UHS icon
Universal Health Services
UHS
+$31.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$28.3M
4
AGN
Allergan Inc
AGN
+$26.3M
5
ZBH icon
Zimmer Biomet
ZBH
+$25.7M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$33.8M
2
A icon
Agilent Technologies
A
+$23.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.7M
4
PODD icon
Insulet
PODD
+$21.7M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$19.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.75%
2 Technology 2%
3 Communication Services 1.82%
4 Industrials 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$39.4M 4.78%
176,698
-69,700
-28% -$14.4M
MDT icon
2
Medtronic
MDT
$107B
$37.6M 4.56%
+589,974
New +$35.8M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$36.9M 4.47%
8,085,945
+3,203,015
+66% +$13.2M
UHS icon
4
Universal Health Services
UHS
$9.12B
$35.4M 4.29%
+369,603
New +$31.9M
HCA icon
5
HCA Healthcare
HCA
$82.2B
$34.7M 4.21%
615,059
-257,530
-30% -$13.6M
RCPT
6
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$32.1M 3.89%
753,660
+442,933
+143% +$15.3M
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$30M 3.64%
723,816
+210,618
+41% +$10.8M
CMRX
8
DELISTED
Chimerix, Inc.
CMRX
$29.3M 3.56%
1,337,150
+442,144
+49% +$8.78M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.4B
$29.1M 3.53%
+468,100
New +$28.3M
AGN
10
DELISTED
Allergan Inc
AGN
$28.8M 3.5%
170,400
+168,614
+9,441% +$26.3M
BHC icon
11
Bausch Health
BHC
$1.75B
$28.7M 3.49%
227,830
-69,306
-23% -$8.84M
ZBH icon
12
Zimmer Biomet
ZBH
$17.4B
$26.6M 3.23%
+263,735
New +$25.7M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$25.6M 3.1%
7,650,268
-846,270
-10% -$1.99M
TRIV
14
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$22.1M 2.69%
+1,540,648
New +$23.4M
TVTY
15
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$21.7M 2.63%
1,234,771
-120,061
-9% -$2.06M
KYTH
16
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$21.5M 2.61%
560,356
+117,030
+26% +$4.09M
A icon
17
Agilent Technologies
A
$36.8B
$19.9M 2.42%
484,938
-595,708
-55% -$23.9M
GMED icon
18
Globus Medical
GMED
$10.3B
$19.9M 2.42%
832,988
-229,964
-22% -$5.55M
HTWR
19
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$19.7M 2.39%
222,926
-69,048
-24% -$6.19M
AMGN icon
20
Amgen
AMGN
$197B
$19.3M 2.34%
+163,254
New +$18.9M
SYK icon
21
Stryker
SYK
$122B
$18M 2.19%
+213,918
New +$17.5M
NUVA
22
DELISTED
NuVasive, Inc.
NUVA
$17.9M 2.17%
502,291
-19,010
-4% -$651K
RAD
23
DELISTED
Rite Aid Corporation
RAD
$17.7M 2.15%
123,693
-66,397
-35% -$9.8M
NSTG
24
DELISTED
NanoString Technologies, Inc.
NSTG
$17M 2.06%
1,133,948
+605,878
+115% +$9.55M
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16.5M 2%
979,446
-21,614
-2% -$357K
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q2 2014 Portfolio in Review

As of Q2 2014, Redmile Group held 69 positions worth $825M, down 1.6% from $838M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Redmile Group's Q2 2014 filing shows 13 new, 13 increased, 19 reduced and 21 closed positions. Its largest new stake was Medtronic: 589,974 shares worth $37.6M. The largest sale was Tenet Healthcare, an estimated $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 80% a quarter earlier, followed by Technology and Communication Services.

  • Redmile Group's largest Q2 2014 buy was Medtronic: 589,974 shares worth $37.6M.
  • Redmile Group added most to Allergan Inc in Q2 2014, an estimated $26.3M increase.
  • Redmile Group's biggest Q2 2014 reduction was Agilent Technologies, cutting an estimated $23.9M.
  • Redmile Group fully exited Tenet Healthcare in Q2 2014, selling an estimated $33.8M.
  • Redmile Group's ten largest holdings make up 40% of its $825M portfolio in Q2 2014.
  • Redmile Group opened 13 new positions and closed 21 in Q2 2014.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $825M.

Based on Redmile Group's 13F filing for Q2 2014, filed 15 Aug 2014.